Graffinity signs drug discovery research collaboration with Genentech

Graffinity Pharmaceuticals, a biopharmaceutical company, has entered into a drug discovery research collaboration with Genentech, a wholly-owned member of the Roche Group. With this collaboration Genentech will gain access to Graffinity's proprietary, fragment-based drug discovery technology.

Under the terms of the agreement, Graffinity will receive technology access fees and optional payments for follow-up chemistry for the generation of novel, small molecule hits against a number of drug targets. Financial details of the transaction were not disclosed.

Kristina Schmidt, CEO of Graffinity, said: "Our label-free, biophysics-based screening technology has shown to be an important element for companies which choose to work with us.

"With the help of this technology we enable partners, such as Genentech, to explore drug targets that would remain white spaces on the map of drug discovery, if researchers were limited to other conventional high-throughput screening techniques."

http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall 
not be liable for errors or delays in the content, or for any actions 
taken in reliance thereon

Related terms: biology, ceo, pharmaceuticals, research, technology